VentFree value Target hospitals and ICUs performing long-term mechanical ventilation to adopt VentFree non-invasive respiratory muscle stimulation, highlighting potential to reduce ventilator days, lower morbidity, and cut care costs for providers.

FDA path Leverage recent Series B funding and board expansion to accelerate FDA clearance initiatives and expand regulatory milestones, presenting a accelerated commercialization opportunity for early adopter institutions.

Strategic partners Engage with strategic investors and HealthDev affiliate networks connected to medical device manufacturing and distribution to facilitate co-marketing, clinical adoption studies, and scaled manufacturing partnerships.

Clinical ROI Quantify and communicate return on investment through shorter ventilation wean times, reduced ICU stays, and lower post-ventilation complications to drive hospital finance committees to pilot or adopt VentFree.

SME to enterprise Position Liberate Medical as a nimble, specialist provider with scalable production through prior partnerships (Valtronic) and a focused product for pulmonology and critical care, appealing to mid-market hospital systems seeking innovative devices with favorable cost of ownership.